Drug or intervention
Ondansetron Clinical Trials
Studies that test Ondansetron, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 93PONV
Amisulpride Injection for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery
This study is a randomized controlled clinical trial focusing on the prevention of postoperative nausea and vomiting (PONV), planned to start in May 2026 and end in April 2027.
- Trial name
- NCT07891312
- Testing
- Amisulpride, Ondansetron
- Volunteers
- 718 people
- Sponsor
- Qianfoshan Hospital
Breast Cancer
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC…
- Trial name
- NCT07455955
- Testing
- Standard antiemetic regimen or Olanzapine antiemetic regimen
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Spinal Anesthesia-Induced Hypotension, Cerebral Oxygenation
Effects of Ondansetron Timing During Spinal Anesthesia for Urologic Surgery
This study will evaluate whether the timing of intravenous ondansetron administration affects cerebral oxygenation and hemodynamic stability in older adults undergoing endoscopic urologic surgery under spinal anesthesia.
- Trial name
- NCT07858149
- Testing
- Ondansetron 8 mg, 0.9 % sodium chloride
- Where
- Turkey (Türkiye)
- Volunteers
- 99 people
- Sponsor
- Istanbul University
Cholera (Disorder)
Ondansetron to Prevent Oral Rehydration Failure in Children With Cholera
This Phase IIa randomized controlled trial will evaluate whether a single oral dose of ondansetron can reduce oral rehydration failure in children and adolescents with suspected or confirmed cholera and active vomiting.
- Trial name
- NCT07795060
- Testing
- Ondansetron, Standard Cholera Care
- Where
- Republic of the Congo
- Volunteers
- 120 people
- Sponsor
- Public Interest Science Center
Healthy Volunteers
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
This study looks at how to reduce nausea and vomiting in people taking KarXT which is used to treat mental health conditions like schizophrenia.
- Trial name
- NCT07681076
- Testing
- KarXT, Trimethobenzamide, Ondansetron
- Where
- 4 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Appendectomy, Laparoscopic, Acute Appendicitis
Feasibility and Safety of a Pediatric ERAS Protocol for Laparoscopic Appendectomy
Acute appendicitis is the most common surgical emergency in children. Despite the widespread adoption of laparoscopic appendectomy, postoperative care still varies widely between institutions, with prolonged fasting, opioid-based…
- Conditions
- Appendectomy, Laparoscopic, Acute Appendicitis, Pediatric Surgery, ERAS
- Trial name
- NCT07643285
- Testing
- Comprehensive 20-Item Pediatric ERAS Protocol
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ahmet Burak Doğan, MD
Intra-operative Hypotension
Preoperative Point of Care Ultrasound Guided Fluid Optimization and Intravenous Ondansetron to Prevent General Anesthesia-Induced Hypotension
Hypotension is a common side-effect of general anesthesia induction and is related to adverse outcomes including significantly increasing risk of one-year mortality.
- Trial name
- NCT05784350
- Testing
- fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Meir Medical Center
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV), Postoperative Nausea and Vomiting
- Trial name
- NCT07868861
- Testing
- NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Breast Cancer, Postoperative Recovery
ERAS Protocols in Breast Conserving Surgery
Enhanced Recovery After Surgery (ERAS) protocols have been of increasing interest in the surgical community for decades. The emphasis has been development of protocols to maximize pain control post-operatively without the use of…
- Trial name
- ERAS (NCT06938581)
- Testing
- ERAS Protocol, Standard Perioperative Care
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- University of Nebraska
Intraoperative Nausea-retching-vomiting Episodes, Spinal Aneshtesia
Routine Antiemetic Prophylaxis for Nonfasted Parturients Undergoing Cesarean Sections Under Spinal Anesthesia
The aim of this prospective randomized double-blind study is to compare the effectiveness of routine antiemetic prophylaxis for the prevention of intraoperative nausea and vomiting (IONV) in non-fasted parturients undergoing…
- Conditions
- Intraoperative Nausea-retching-vomiting Episodes, Spinal Aneshtesia, Ceserean Section, Antiemetic Therapy
- Trial name
- NCT07740577
- Testing
- Ondansetron 4mg, metoclopramide
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Sanliurfa Education and Research Hospital
Completed, with results posted
All 118Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
Background: Drugs known as poly-adenosine diphosphate ribose polymerase (PARP) inhibitors are known to help stop tumor growth in patients with breast, ovarian cancers and many other cancers including prostate and pancreatic…
- Trial name
- NCT04209595
- Testing
- PLX038, Rucaparib, Ondansetron
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Perioperative Optimization
Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
This REMAP Periop ERP domain study falls under the Periop Core Protocol, which compares the different recommended strategies for enhancing recovery through the use of various standard of care treatments before, during and after…
- Trial name
- NCT04606264
- Testing
- Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine
- Where
- 3 sites in United States
- Volunteers
- 3,395 people
- Sponsor
- Jennifer Holder-Murray
Nausea and Vomiting, Postoperative, Cesarean Section Complications
Dexamethasone vs Ondansetron After Cesarean Delivery
The goal of this clinical trial is to compare medications in women having a cesarean delivery. The main question it aims to answer are: Which medication is better to use as a first-line prevention agent for nausea and vomiting…
- Trial name
- NCT05692245
- Testing
- Ondansetron, Dexamethasone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Beth Israel Deaconess Medical Center
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapy-induced Nausea and Vomiting
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (> 24-120…
- Trial name
- NCT02106494
- Testing
- APF530, Ondansetron, Fosaprepitant
- Where
- 7 sites in United States
- Volunteers
- 942 people
- Sponsor
- Heron Therapeutics